Pliant Therapeutics Inc
PLRX
Company Profile
Business description
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
Contact
260 Littlefield Avenue
South San FranciscoCA94080
USAT: +1 650 481-6770
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
166
Stocks News & Analysis
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
With increased AI spending and hopes of future data center expansion, here’s what we think of Nvidia stock.
stocks
Is this overpriced ASX share too much of a gamble?
We raise our fair value after strong results but shares are pricey.
stocks
ASX players that might thrive under a Trump administration
Recent election results have sent US markets into a record-high rally however implications remain mixed for the Australian share market. See our top ASX picks that could do better under a second Trump administration.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,479.90 | 29.00 | 0.34% |
| CAC 40 | 7,311.80 | 94.97 | 1.32% |
| DAX 40 | 19,263.70 | 260.59 | 1.37% |
| Dow JONES (US) | 43,735.75 | 222.44 | -0.51% |
| FTSE 100 | 8,071.19 | 40.86 | 0.51% |
| HKSE | 19,435.81 | 387.64 | -1.96% |
| NASDAQ | 19,112.47 | 118.25 | -0.61% |
| Nikkei 225 | 38,535.70 | 185.96 | -0.48% |
| NZX 50 Index | 12,692.94 | 18.45 | 0.15% |
| S&P 500 | 5,951.67 | 33.71 | -0.56% |
| S&P/ASX 200 | 8,224.00 | 30.60 | 0.37% |
| SSE Composite Index | 3,379.84 | 59.44 | -1.73% |